Replies to post #624 on Biotech Values

[isolution]

Drug delivery

So, yes, these companies should attempt to develop a local-delivery mechanism, but this work should proceed in parallel with the rest of the clinical program.

Dew, thanks for your insight, I perfectly agree with your comments and I think Oxigene has already taken that into account.
Your might have a look at their patent application at:

http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsea...
number 20030181531, title "Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases", examples at the end of the text describe several administration ways, very interesting.